• Bpifrance supports the development of Crossject’s products portfolio

    CROSSJECT announces that it has been awarded a grant of €6.7 million by Bpifrance, repayable over three years, as part of the Industrial Projects of the Future (Projets Industriels d’Avenir or PIAVE) scheme. This funding gives CROSSJECT the resources to develop three new proprietary drugs for use in emergency situations.

    Read the press release

    Read more
  • Crossject in New York to meet investors

    CROSSJECT will participate to the 2016 Emerging leaders in European Healthcare Conferencetaking place in New York on October 22nd 2015. The event is an opportunity for CROSSJECT to draw the investors  attention on their unique solution and wide potential proprietary product portfolio. CROSSJECT will detail its value maximization strategy, based on the signature of distribution deals for its own products.

    Read more


  • 11/26/2015

    Crossject will be present at Biotech Showcase 2016

    Come and meet us in San Francisco, January 11th to 13th, for the Biotech Showcase conference, the reference event in terms of investments and partnerships for executives and investors in the life sciences sector.
    Contact Tim Muller: or  / Mobile +33 (0)645523540 / +33(0)602510791 / skype id: timotheemuller

    Read more
  • 11/25/2015

    Crossject will be present at Bio Europe 2016

    BIO Europe Crossject will be present at the BIO Europe convention, the event dedicated to partnerships that brings together leaders from the biopharmaceutical industry. Meet us in Stockholm, April 4th to 6th.
    Contact Tim Muller: or  / Mobile +33 (0)645523540 / +33(0)602510791 / skype id: timotheemuller

    Read more


Discover our needle-free self injectable solution

The desire for safer and more user-friendly injection device to prevent needle-stick injuries...

more videos